KO’d By Allergy Failure, Circassia Looks To Respiratory Pipeline For Second Wind
Circassia is shifting its focus on its respiratory portfolio following the disappointing Phase III results of its cat allergy drug in June, which saw the company’s share price plummet by more than 60%.
You may also be interested in...
At a recent UK health-care conference, experts from across the health-care sector and investment community came together to explore alternative financing tactics to support businesses in their growth plans. UK investors were warned that if they continue to be overly cautious, they might risk losing out to their transatlantic counterparts.
The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.
Circassia is acquiring two asthma product developers for more than £188m but this doesn't mean the company is dropping its allergy focus.